These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 23228225)
21. Cost-effectiveness study of three antimalarial drug combinations in Tanzania. Wiseman V; Kim M; Mutabingwa TK; Whitty CJ PLoS Med; 2006 Oct; 3(10):e373. PubMed ID: 17032059 [TBL] [Abstract][Full Text] [Related]
26. WHO reports progress in malaria control. Collier R CMAJ; 2010 Feb; 182(2):E105-6. PubMed ID: 20026636 [No Abstract] [Full Text] [Related]
27. Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. Snow RW; Eckert E; Teklehaimanot A Trends Parasitol; 2003 Aug; 19(8):363-9. PubMed ID: 12901938 [TBL] [Abstract][Full Text] [Related]
28. Artesunate for severe malaria. Lancet; 2011 Apr; 377(9776):1466. PubMed ID: 21531257 [No Abstract] [Full Text] [Related]
29. Drug subsidy could help Tanzania tackle malaria. Samarasekera U Lancet; 2008 Apr; 371(9622):1403-6. PubMed ID: 18446925 [No Abstract] [Full Text] [Related]
30. Global fund changes tack on malaria therapy. Butler D Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190315 [No Abstract] [Full Text] [Related]
31. Artemisinin resistance--modelling the potential human and economic costs. Lubell Y; Dondorp A; Guérin PJ; Drake T; Meek S; Ashley E; Day NP; White NJ; White LJ Malar J; 2014 Nov; 13():452. PubMed ID: 25418416 [TBL] [Abstract][Full Text] [Related]
32. Drug dispensing practices during implementation of artemisinin-based combination therapy at health facilities in rural Tanzania, 2002-2005. Thwing JI; Njau JD; Goodman C; Munkondya J; Kahigwa E; Bloland PB; Mkikima S; Mills A; Abdulla S; Kachur SP Trop Med Int Health; 2011 Mar; 16(3):272-9. PubMed ID: 21226795 [TBL] [Abstract][Full Text] [Related]
33. Implementation of the Affordable Medicines for Malaria Facility (AMFm) in Ghana: processes, challenges and achievements. Malm KL; Segbaya S; Forson I; Gakpey KD; Sampong LB; Adjei EA; Bart-Plange C J Public Health Policy; 2013 May; 34(2):302-14. PubMed ID: 23575513 [TBL] [Abstract][Full Text] [Related]
34. The economic case for combating malaria. Purdy M; Robinson M; Wei K; Rublin D Am J Trop Med Hyg; 2013 Nov; 89(5):819-823. PubMed ID: 24197172 [TBL] [Abstract][Full Text] [Related]
35. The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural Tanzania. Njau JD; Goodman CA; Kachur SP; Mulligan J; Munkondya JS; McHomvu N; Abdulla S; Bloland P; Mills A Malar J; 2008 Jan; 7():4. PubMed ID: 18179716 [TBL] [Abstract][Full Text] [Related]
36. Should new antimalarial drugs be subsidized? Laxminarayan R; Parry IW; Smith DL; Klein EY J Health Econ; 2010 May; 29(3):445-56. PubMed ID: 20381182 [TBL] [Abstract][Full Text] [Related]
37. Management of malaria in pregnancy. Rogerson SJ Indian J Med Res; 2017 Sep; 146(3):328-333. PubMed ID: 29355138 [TBL] [Abstract][Full Text] [Related]
38. An affordable antimalarial. Tenenbaum DJ Environ Health Perspect; 2004 Jan; 112(1):A25. PubMed ID: 14714543 [No Abstract] [Full Text] [Related]
39. How artemisinin-containing combination therapies slow the spread of antimalarial drug resistance. Hastings I Trends Parasitol; 2011 Feb; 27(2):67-72. PubMed ID: 20971040 [TBL] [Abstract][Full Text] [Related]
40. Estimating antimalarial drugs consumption in Africa before the switch to artemisinin-based combination therapies (ACTs). Kindermans JM; Vandenbergh D; Vreeke E; Olliaro P; D'Altilia JP Malar J; 2007 Jul; 6():91. PubMed ID: 17623092 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]